Benitec Biopharma Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Durable Responses to Low Dose Investigational Gene Therapy BB-301 in Patients with Oculopharyngeal Muscular Dystrophy with Dysphagia at 12-Months and 24-Months and Improved Depth of Response to High...
Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point, with both doses demonstrating disease modifying outcomesBB-301 Phase 1b/2a interim clinical study results selected for oral presentation
Benitec Biopharma Inc. reported earnings results for the third quarter and nine months ended March 31, 2026. For the third quarter, the company reported net loss was USD 11.94 million compared to USD...
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 36.84 percent increase over losses of $(0.38) per share from
Evercore ISI Group analyst Cory Kasimov initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $25.
- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 Patient, and interim clinical results for the first Cohort 2 Patient - BB-301 is the only clinical-stage therapeutic agent in development for the treatment of dysphagia in patients diagnosed with OPMD HAYWARD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:
HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, is hosting an Industry Forum Breakfast and presentation on Tuesday, March 10, at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The presentation will high
Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Benitec Biopharma (NASDAQ:BNTC) with a Buy and maintains $32 price target.
- Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom burden - OPMD Patients treated with low dose BB-301 experienced highly durable improvements, with clinical and radiographic improvements continuing to deepen two years post BB-301 treatment -The first OPMD Patient treated with high dose BB-301 experienced an extraordinarily robust dose-response
-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results for the first Cohort 2 Patient will be reported in a late-breaking poster presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference on March 9, 2026- HAYWARD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma
-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Benitec Biopharma stock rises on positive 12-month data for its lead gene therapy BB-301, overshadowing a quarterly earnings miss.
-The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month follow-up timepoint demonstrating durable response to BB-301- -Patient 1 of Cohort 1 completed the 24-month follow-up timepoint, and at the 24-month post-treatment timepoint Patient 1 continued to experience the disease-modifying effects of BB-301, with deepening improvements in post-
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.22) by 16.59 percent. This is unchanged from the same period last year.
Benitec Biopharma Inc. reports 100% responder rates for BB-301 with a mid-2026 FDA meeting ahead. See why BNTC stock is upgraded to buy.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 338.2K | $3.60M | 0.00% | Added+38.0% | 2026-03-31 |
| FidelityFMR | fundamental | 1.7K | $17.61K | 0.00% | Added+26.2% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-09-22upcoming | -0.28 | — | — |
| 2026-05-14 | -0.28 | -0.24 | +12.73% |
| 2026-02-12 | -0.23 | -0.26 | -15.04% |
| 2025-11-14 | -0.36 | -0.22 | +38.20% |
| 2025-09-22 | -0.31 | -0.42 | -34.25% |
| 2025-05-14 | -0.35 | -0.24 | +31.10% |
| 2025-02-14 | -0.78 | -0.33 | +57.46% |
| 2024-11-14 | -0.55 | -0.48 | +12.73% |
| 2024-05-13 | -0.78 | -1.64 | -110.26% |
| 2024-02-13 | -0.39 | -2.64 | -576.92% |
| 2023-11-13 | -0.51 | -2.76 | -441.18% |
| 2023-05-15 | -3.40 | -2.72 | +20.00% |
| 2023-02-13 | -1.87 | -3.40 | -81.82% |
| 2022-11-10 | -4.25 | -7.99 | -88.00% |
| 2022-09-02 | -4.76 | -10.54 | -121.43% |
| 2022-05-16 | -7.48 | -6.80 | +9.09% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BNTC | -3.26% | +10.52% | -14.18% | -24.74% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -6.23% | +15.15% | -10.74% | -37.43% |